Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genentech Adds Patient Assistance Program Along With Avastin Lung Cancer Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

Program similar to Amgen’s for Vectibix.

You may also be interested in...



Genentech Watchers Weigh Deeper Meaning Of Avastin’s Approval

FDA’s breast-cancer decision not a universal surprise, and there’s still risk in RIBBON-1.

Genentech Watchers Weigh Deeper Meaning Of Avastin’s Approval

FDA’s breast-cancer decision not a universal surprise, and there’s still risk in RIBBON-1.

Roche Considers Pricing Flexibility For Avastin In Europe

Similar to Genentech’s price cap on Avastin in the U.S., Roche is evaluating “creative” pricing approaches following breast cancer approval.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS063180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel